Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2300079201Phase 4Recruiting
Phase 4, open-label, single-arm trial of azacitidine, tucidinostat and mitoxantrone in angioimmunoblastic T-cell lymphoma (AITL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete response rate. Started Dec 2023; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2300079201.